Last updated: February 28, 2024
Sponsor: University of Missouri-Columbia
Overall Status: Completed
Phase
N/A
Condition
Autism
Treatment
Propranolol
Placebo
Clinical Study ID
NCT02428205
2001935
Ages 3-10 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diagnosis of autism spectrum disorder (ASD), defined in this study by the DSM-Vcriteria plus Autism Diagnostic Observation Schedule (ADOS) criteria for Autism.
- Aged 3-8
- Participants must also be enrolled in an early behavioral intervention program at theThompson Center or another institution in Missouri for the duration of the study.
Exclusion
Exclusion Criteria:
- Non-autism learning disability (e.g. dyslexia)
- Major psychiatric diagnosis (e.g. major depression, schizophrenia, bipolar disorder)
- Other neurological diagnosis
- Major head trauma
- Any of the following exclusionary criteria related to propranolol (diabetes, reactiveairway/pulmonary disease, thyroid disease, bradyarrhythmias, unexplained syncope,narrow angle glaucoma, known hypersensitivity/adverse reaction to beta-blockers,potentially interacting drugs, underweight < 15 kg)
- Any of the following exclusionary criteria related to the use of electrocardiogram (history of rash from adhesives)
- Any of the following exclusionary criteria related to the pupillary reflex measurement (uncorrectable visual acuity impairment).
- Participants with a heart rate of less than 60 or a systolic blood pressure of lessthan 75 at the outset of the study will be excluded.
Study Design
Total Participants: 10
Treatment Group(s): 2
Primary Treatment: Propranolol
Phase:
Study Start date:
April 01, 2015
Estimated Completion Date:
November 01, 2022
Study Description
Connect with a study center
Thompson Center for Autism & Neurodevelopmental Disorders
Columbia, Missouri 65211
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.